-
1
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
[PMID: 9196156]
-
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413 [PMID: 9196156]
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
Cripps, M.C.7
Portenoy, R.K.8
Storniolo, A.M.9
Tarassoff, P.10
Nelson, R.11
Dorr, F.A.12
Stephens, C.D.13
Von Hoff, D.D.14
-
2
-
-
77955635233
-
Cancer statistics, 2010
-
PMID: 20610543
-
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300 [PMID: 20610543 DOI: 10.3322/caac.20073]
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
3
-
-
0029835349
-
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
-
[PMID: 8862723]
-
Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557 [PMID: 8862723]
-
(1996)
Anticancer Drugs
, vol.7
, pp. 548-557
-
-
Shirasaka, T.1
Shimamato, Y.2
Ohshimo, H.3
Yamaguchi, M.4
Kato, T.5
Yonekura, K.6
Fukushima, M.7
-
4
-
-
0023250474
-
Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts
-
[PMID: 3114201]
-
Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78: 748-755 [PMID: 3114201]
-
(1987)
Jpn J Cancer Res
, vol.78
, pp. 748-755
-
-
Tatsumi, K.1
Fukushima, M.2
Shirasaka, T.3
Fujii, S.4
-
5
-
-
0027227591
-
Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats
-
[PMID: 7689420]
-
Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004-4009 [PMID: 7689420]
-
(1993)
Cancer Res
, vol.53
, pp. 4004-4009
-
-
Shirasaka, T.1
Shimamoto, Y.2
Fukushima, M.3
-
6
-
-
71249128928
-
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study
-
PMID: 19818685
-
Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1069 [PMID: 19818685 DOI: 10.1016/S1470-2045(09)70259-1]
-
(2009)
Lancet Oncol
, vol.10
, pp. 1063-1069
-
-
Boku, N.1
Yamamoto, S.2
Fukuda, H.3
Shirao, K.4
Doi, T.5
Sawaki, A.6
Koizumi, W.7
Saito, H.8
Yamaguchi, K.9
Takiuchi, H.10
Nasu, J.11
Ohtsu, A.12
-
7
-
-
77956150646
-
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: A randomised phase 2/3 non-inferiority study (FIRIS study)
-
PMID: 20708966
-
Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010; 11: 853-860 [PMID: 20708966 DOI: 10.1016/S1470-2045(10)70181-9]
-
(2010)
Lancet Oncol
, vol.11
, pp. 853-860
-
-
Muro, K.1
Boku, N.2
Shimada, Y.3
Tsuji, A.4
Sameshima, S.5
Baba, H.6
Satoh, T.7
Denda, T.8
Ina, K.9
Nishina, T.10
Yamaguchi, K.11
Takiuchi, H.12
Esaki, T.13
Tokunaga, S.14
Kuwano, H.15
Komatsu, Y.16
Watanabe, M.17
Hyodo, I.18
Morita, S.19
Sugihara, K.20
more..
-
8
-
-
84888130928
-
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): An open-label, non-inferiority, randomised phase 3 trial
-
PMID: 24225157
-
Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 2013; 14: 1278-1286 [PMID: 24225157 DOI: 10.1016/S1470-2045(13)70490-X]
-
(2013)
Lancet Oncol
, vol.14
, pp. 1278-1286
-
-
Yamada, Y.1
Takahari, D.2
Matsumoto, H.3
Baba, H.4
Nakamura, M.5
Yoshida, K.6
Yoshida, M.7
Iwamoto, S.8
Shimada, K.9
Komatsu, Y.10
Sasaki, Y.11
Satoh, T.12
Takahashi, K.13
Mishima, H.14
Muro, K.15
Watanabe, M.16
Sakata, Y.17
Morita, S.18
Shimada, Y.19
Sugihara, K.20
more..
-
9
-
-
40749153540
-
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial
-
PMID: 18282805
-
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221 [PMID: 18282805 DOI: 10.1016/S1470-2045(08)70035-4]
-
(2008)
Lancet Oncol
, vol.9
, pp. 215-221
-
-
Koizumi, W.1
Narahara, H.2
Hara, T.3
Takagane, A.4
Akiya, T.5
Takagi, M.6
Miyashita, K.7
Nishizaki, T.8
Kobayashi, O.9
Takiyama, W.10
Toh, Y.11
Nagaie, T.12
Takagi, S.13
Yamamura, Y.14
Yanaoka, K.15
Orita, H.16
Takeuchi, M.17
-
10
-
-
84880047829
-
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study
-
PMID: 23547081
-
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640-1648 [PMID: 23547081 DOI: 10.1200/JCO.2012.43.3680]
-
(2013)
J Clin Oncol
, vol.31
, pp. 1640-1648
-
-
Ueno, H.1
Ioka, T.2
Ikeda, M.3
Ohkawa, S.4
Yanagimoto, H.5
Boku, N.6
Fukutomi, A.7
Sugimori, K.8
Baba, H.9
Yamao, K.10
Shimamura, T.11
Sho, M.12
Kitano, M.13
Cheng, A.L.14
Mizumoto, K.15
Chen, J.S.16
Furuse, J.17
Funakoshi, A.18
Hatori, T.19
Yamaguchi, T.20
Egawa, S.21
Sato, A.22
Ohashi, Y.23
Okusaka, T.24
Tanaka, M.25
more..
-
11
-
-
84875007577
-
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study)
-
abstr 145
-
Uesaka K, Fukutomi A, Boku N, Kanemoto H, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Nakamura T, Kanai M, Hirano S, Yoshikawa Y, Ohashi Y. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 2012; 30 (suppl): abstr 145
-
(2012)
J Clin Oncol
, vol.30
-
-
Uesaka, K.1
Fukutomi, A.2
Boku, N.3
Kanemoto, H.4
Konishi, M.5
Matsumoto, I.6
Kaneoka, Y.7
Shimizu, Y.8
Nakamori, S.9
Sakamoto, H.10
Morinaga, S.11
Kainuma, O.12
Imai, K.13
Sata, N.14
Hishinuma, S.15
Nakamura, T.16
Kanai, M.17
Hirano, S.18
Yoshikawa, Y.19
Ohashi, Y.20
more..
-
12
-
-
84880073605
-
JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer
-
abstr 4008
-
Fukutomi A, Uesaka K, Boku N, Kanemoto H, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Nakamura T, Kanai M, Hirano S, Yoshikawa Y, Ohashi Y. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 2013; 31 (suppl): abstr 4008
-
(2013)
J Clin Oncol
, vol.31
-
-
Fukutomi, A.1
Uesaka, K.2
Boku, N.3
Kanemoto, H.4
Konishi, M.5
Matsumoto, I.6
Kaneoka, Y.7
Shimizu, Y.8
Nakamori, S.9
Sakamoto, H.10
Morinaga, S.11
Kainuma, O.12
Imai, K.13
Sata, N.14
Hishinuma, S.15
Nakamura, T.16
Kanai, M.17
Hirano, S.18
Yoshikawa, Y.19
Ohashi, Y.20
more..
-
13
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
-
[PMID: 17452677]
-
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966 [PMID: 17452677]
-
(2007)
J Clin Oncol
, vol.25
, pp. 1960-1966
-
-
Moore, M.J.1
Goldstein, D.2
Hamm, J.3
Figer, A.4
Hecht, J.R.5
Gallinger, S.6
Au, H.J.7
Murawa, P.8
Walde, D.9
Wolff, R.A.10
Campos, D.11
Lim, R.12
Ding, K.13
Clark, G.14
Voskoglou-Nomikos, T.15
Ptasynski, M.16
Parulekar, W.17
-
14
-
-
79955921754
-
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
-
PMID: 21561347
-
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]
-
(2011)
N Engl J Med
, vol.364
, pp. 1817-1825
-
-
Conroy, T.1
Desseigne, F.2
Ychou, M.3
Bouché, O.4
Guimbaud, R.5
Bécouarn, Y.6
Adenis, A.7
Raoul, J.L.8
Gourgou-Bourgade, S.9
De La Fouchardière, C.10
Bennouna, J.11
Bachet, J.B.12
Khemissa-Akouz, F.13
Péré-Vergé, D.14
Delbaldo, C.15
Assenat, E.16
Chauffert, B.17
Michel, P.18
Montoto-Grillot, C.19
Ducreux, M.20
more..
-
15
-
-
84886741654
-
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
-
PMID: 24131140
-
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]
-
(2013)
N Engl J Med
, vol.369
, pp. 1691-1703
-
-
Von Hoff, D.D.1
Ervin, T.2
Arena, F.P.3
Chiorean, E.G.4
Infante, J.5
Moore, M.6
Seay, T.7
Tjulandin, S.A.8
Ma, W.W.9
Saleh, M.N.10
Harris, M.11
Reni, M.12
Dowden, S.13
Laheru, D.14
Bahary, N.15
Ramanathan, R.K.16
Tabernero, J.17
Hidalgo, M.18
Goldstein, D.19
Van Cutsem, E.20
Wei, X.21
Iglesias, J.22
Renschler, M.F.23
more..
-
16
-
-
23844431643
-
An early phase II study of S-1 in patients with metastatic pancreatic cancer
-
[PMID: 16006754]
-
Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005; 68: 171-178 [PMID: 16006754]
-
(2005)
Oncology
, vol.68
, pp. 171-178
-
-
Ueno, H.1
Okusaka, T.2
Ikeda, M.3
Takezako, Y.4
Morizane, C.5
-
17
-
-
38049048176
-
A late phase II study of S-1 for metastatic pancreatic cancer
-
[PMID: 17520253]
-
Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, Saito H. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2008; 61: 615-621 [PMID: 17520253]
-
(2008)
Cancer Chemother Pharmacol
, vol.61
, pp. 615-621
-
-
Okusaka, T.1
Funakoshi, A.2
Furuse, J.3
Boku, N.4
Yamao, K.5
Ohkawa, S.6
Saito, H.7
-
18
-
-
0034327360
-
Equilibrative- sensitive nucleoside transporter and its role in gemcitabine sensitivity
-
[PMID: 11085530]
-
Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative- sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000; 60: 6075-6079 [PMID: 11085530]
-
(2000)
Cancer Res
, vol.60
, pp. 6075-6079
-
-
Rauchwerger, D.R.1
Firby, P.S.2
Hedley, D.W.3
Moore, M.J.4
-
19
-
-
33745258389
-
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
-
[PMID: 16721372]
-
Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006; 94: 1575-1579 [PMID: 16721372]
-
(2006)
Br J Cancer
, vol.94
, pp. 1575-1579
-
-
Nakamura, K.1
Yamaguchi, T.2
Ishihara, T.3
Sudo, K.4
Kato, H.5
Saisho, H.6
-
20
-
-
79961094078
-
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer
-
PMID: 21715364
-
Ueno H, Okusaka T, Furuse J, Yamao K, Funakoshi A, Boku N, Ohkawa S, Yokosuka O, Tanaka K, Moriyasu F, Nakamori S, Sato T. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol 2011; 41: 953-958 [PMID: 21715364 DOI: 10.1093/jjco/hyr090]
-
(2011)
Jpn J Clin Oncol
, vol.41
, pp. 953-958
-
-
Ueno, H.1
Okusaka, T.2
Furuse, J.3
Yamao, K.4
Funakoshi, A.5
Boku, N.6
Ohkawa, S.7
Yokosuka, O.8
Tanaka, K.9
Moriyasu, F.10
Nakamori, S.11
Sato, T.12
-
21
-
-
75549083878
-
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
-
PMID: 19578850
-
Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol 2010; 65: 527-536 [PMID: 19578850 DOI: 10.1007/s00280-009-1059-9]
-
(2010)
Cancer Chemother Pharmacol
, vol.65
, pp. 527-536
-
-
Oh, D.Y.1
Cha, Y.2
Choi, I.S.3
Yoon, S.Y.4
Choi, I.K.5
Kim, J.H.6
Oh, S.C.7
Kim, C.D.8
Kim, J.S.9
Bang, Y.J.10
Kim, Y.H.11
-
22
-
-
68149117513
-
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer
-
PMID: 19151975
-
Lee GW, Kim HJ, Ju JH, Kim SH, Kim HG, Kim TH, Kim HJ, Jeong CY, Kang JH. Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009; 64: 707-713 [PMID: 19151975 DOI: 10.1007/s00280-008-0918-0]
-
(2009)
Cancer Chemother Pharmacol
, vol.64
, pp. 707-713
-
-
Lee, G.W.1
Kim, H.J.2
Ju, J.H.3
Kim, S.H.4
Kim, H.G.5
Kim, T.H.6
Kim, H.J.7
Jeong, C.Y.8
Kang, J.H.9
-
23
-
-
58149389383
-
S-1 and gemcitabine as an outpatient- based regimen in patients with advanced or metastatic pancreatic cancer
-
PMID: 19060295
-
Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, Ryoo HM, Lee SA, Hyun MS. S-1 and gemcitabine as an outpatient- based regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol 2009; 39: 49-53 [PMID: 19060295 DOI: 10.1093/jjco/hyn126]
-
(2009)
Jpn J Clin Oncol
, vol.39
, pp. 49-53
-
-
Kim, M.K.1
Lee, K.H.2
Jang, B.I.3
Kim, T.N.4
Eun, J.R.5
Bae, S.H.6
Ryoo, H.M.7
Lee, S.A.8
Hyun, M.S.9
-
24
-
-
84862006429
-
A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEM-SAP study
-
PMID: 22555398
-
Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, Kogure H, Matsubara S, Ito Y, Togawa O, Arizumi T, Hirano K, Tada M, Omata M, Koike K. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEM-SAP study. Br J Cancer 2012; 106: 1934-1939 [PMID: 22555398 DOI: 10.1038/bjc.2012.183]
-
(2012)
Br J Cancer
, vol.106
, pp. 1934-1939
-
-
Nakai, Y.1
Isayama, H.2
Sasaki, T.3
Sasahira, N.4
Tsujino, T.5
Toda, N.6
Kogure, H.7
Matsubara, S.8
Ito, Y.9
Togawa, O.10
Arizumi, T.11
Hirano, K.12
Tada, M.13
Omata, M.14
Koike, K.15
-
25
-
-
84862290986
-
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)
-
PMID: 22249272
-
Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol 2012; 69: 1197-1204 [PMID: 22249272 DOI: 10.1007/s00280-012-1822-1]
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, pp. 1197-1204
-
-
Ozaka, M.1
Matsumura, Y.2
Ishii, H.3
Omuro, Y.4
Itoi, T.5
Mouri, H.6
Hanada, K.7
Kimura, Y.8
Maetani, I.9
Okabe, Y.10
Tani, M.11
Ikeda, T.12
Hijioka, S.13
Watanabe, R.14
Ohoka, S.15
Hirose, Y.16
Suyama, M.17
Egawa, N.18
Sofuni, A.19
Ikari, T.20
Nakajima, T.21
more..
-
26
-
-
84896042155
-
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
-
PMID: 24322377
-
Sudo K, Ishihara T, Hirata N, Ozawa F, Ohshima T, Azemoto R, Shimura K, Nihei T, Nishino T, Nakagawa A, Nakamura K, Hara T, Tada M, Mikata R, Tawada K, Yokosuka O, Nakaji S, Yamaguchi T. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemother Pharmacol 2014; 73: 389-396 [PMID: 24322377 DOI: 10.1007/s00280-013-2368-6]
-
(2014)
Cancer Chemother Pharmacol
, vol.73
, pp. 389-396
-
-
Sudo, K.1
Ishihara, T.2
Hirata, N.3
Ozawa, F.4
Ohshima, T.5
Azemoto, R.6
Shimura, K.7
Nihei, T.8
Nishino, T.9
Nakagawa, A.10
Nakamura, K.11
Hara, T.12
Tada, M.13
Mikata, R.14
Tawada, K.15
Yokosuka, O.16
Nakaji, S.17
Yamaguchi, T.18
-
27
-
-
0036682041
-
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
-
[PMID: 12149301]
-
Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275 [PMID: 12149301]
-
(2002)
J Clin Oncol
, vol.20
, pp. 3270-3275
-
-
Berlin, J.D.1
Catalano, P.2
Thomas, J.P.3
Kugler, J.W.4
Haller, D.G.5
Benson, A.B.6
-
28
-
-
34250180939
-
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
-
[PMID: 17538165]
-
Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-2217 [PMID: 17538165]
-
(2007)
J Clin Oncol
, vol.25
, pp. 2212-2217
-
-
Herrmann, R.1
Bodoky, G.2
Ruhstaller, T.3
Glimelius, B.4
Bajetta, E.5
Schüller, J.6
Saletti, P.7
Bauer, J.8
Figer, A.9
Pestalozzi, B.10
Köhne, C.H.11
Mingrone, W.12
Stemmer, S.M.13
Tàmas, K.14
Kornek, G.V.15
Koeberle, D.16
Cina, S.17
Bernhard, J.18
Dietrich, D.19
Scheithauer, W.20
more..
-
29
-
-
73949135518
-
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
-
PMID: 19858379
-
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518 [PMID: 19858379 DOI: 10.1200/JCO.2009.24.2446]
-
(2009)
J Clin Oncol
, vol.27
, pp. 5513-5518
-
-
Cunningham, D.1
Chau, I.2
Stocken, D.D.3
Valle, J.W.4
Smith, D.5
Steward, W.6
Harper, P.G.7
Dunn, J.8
Tudur-Smith, C.9
West, J.10
Falk, S.11
Crellin, A.12
Adab, F.13
Thompson, J.14
Leonard, P.15
Ostrowski, J.16
Eatock, M.17
Scheithauer, W.18
Herrmann, R.19
Neoptolemos, J.P.20
more..
-
30
-
-
84867072111
-
Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer
-
abstr 311
-
Ku GY, Haaland B, Ioka T, Isayama H, Nakai Y, Cheng AL, Okusaka T, de Lima Lopes G. Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer. J Clin Oncol 2012; 30 (suppl): abstr 311
-
(2012)
J Clin Oncol
, vol.30
-
-
Ku, G.Y.1
Haaland, B.2
Ioka, T.3
Isayama, H.4
Nakai, Y.5
Cheng, A.L.6
Okusaka, T.7
De Lima Lopes, G.8
-
31
-
-
84912069926
-
Efficacy and safety of Gemcitabine plus S-1 treatment in locally advanced and metastatic pancreatic cancer: A pooled analysis of three randomized trials using updated individual patient data
-
abstract 2595
-
Ishii H, Okusaka T, Ikari T, Isayama H, Furuse J, Nakai Y, Imai S, Okamura S, Hamada C. Efficacy and safety of Gemcitabine plus S-1 treatment in locally advanced and metastatic pancreatic cancer: A pooled analysis of three randomized trials using updated individual patient data. ECCO 2013; abstract 2595
-
(2013)
ECCO
-
-
Ishii, H.1
Okusaka, T.2
Ikari, T.3
Isayama, H.4
Furuse, J.5
Nakai, Y.6
Imai, S.7
Okamura, S.8
Hamada, C.9
-
32
-
-
79960019683
-
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
-
PMID: 21565490
-
Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47: 1676-1681 [PMID: 21565490 DOI: 10.1016/j.ejca.2011.04.011]
-
(2011)
Eur J Cancer
, vol.47
, pp. 1676-1681
-
-
Pelzer, U.1
Schwaner, I.2
Stieler, J.3
Adler, M.4
Seraphin, J.5
Dörken, B.6
Riess, H.7
Oettle, H.8
-
33
-
-
48949087810
-
A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
-
abstr 4508
-
Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26 (suppl): abstr 4508
-
(2008)
J Clin Oncol
, vol.26
-
-
Pelzer, U.1
Schwaner, I.2
Stieler, J.3
Adler, M.4
Seraphin, J.5
Dörken, B.6
Riess, H.7
Oettle, H.8
-
34
-
-
57149136453
-
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
-
PMID: 18398614
-
Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 313-319 [PMID: 18398614 DOI: 10.1007/s00280-008-0741-7]
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, pp. 313-319
-
-
Morizane, C.1
Okusaka, T.2
Furuse, J.3
Ishii, H.4
Ueno, H.5
Ikeda, M.6
Nakachi, K.7
Najima, M.8
Ogura, T.9
Suzuki, E.10
-
35
-
-
79953804276
-
Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
-
PMID: 20352216
-
Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 2011; 67: 249-254 [PMID: 20352216 DOI: 10.1007/s00280-010-1311-3]
-
(2011)
Cancer Chemother Pharmacol
, vol.67
, pp. 249-254
-
-
Sudo, K.1
Yamaguchi, T.2
Nakamura, K.3
Denda, T.4
Hara, T.5
Ishihara, T.6
Yokosuka, O.7
-
36
-
-
84994835150
-
Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabinerefractory pancreatic cancer
-
abstr 263
-
Mizuno N, Yamao K, Komatsu Y, Munakata M, Ishiguro A, Yamaguchi T, Ohkawa S, Kida M, Ioka T, Takeda K, Kudo T, Kitano M, Iguchi H, Tsuji A, Ito T, Tanaka M, Furuse J, Hamada C, Sakata Y. Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabinerefractory pancreatic cancer. J Clin Oncol 2012; 30 (suppl 34): abstr 263
-
(2012)
J Clin Oncol
, vol.30
-
-
Mizuno, N.1
Yamao, K.2
Komatsu, Y.3
Munakata, M.4
Ishiguro, A.5
Yamaguchi, T.6
Ohkawa, S.7
Kida, M.8
Ioka, T.9
Takeda, K.10
Kudo, T.11
Kitano, M.12
Iguchi, H.13
Tsuji, A.14
Ito, T.15
Tanaka, M.16
Furuse, J.17
Hamada, C.18
Sakata, Y.19
-
37
-
-
84912069732
-
Randomized phase II trial of S-1 versus S-1 plus oxaliplatin (SOX) in patients with GEM refractory pancreatic cancer
-
abstract 1437
-
Okusaka T, Ohkawa S, Isayama H, Fukutomi A, Yamaguchi K, Ikeda M, Funakoshi A, Nagase M, Nakamori S, Hamamoto Y. Randomized phase II trial of S-1 versus S-1 plus oxaliplatin (SOX) in patients with GEM refractory pancreatic cancer. ESMO 2012; abstract 1437
-
(2012)
ESMO
-
-
Okusaka, T.1
Ohkawa, S.2
Isayama, H.3
Fukutomi, A.4
Yamaguchi, K.5
Ikeda, M.6
Funakoshi, A.7
Nagase, M.8
Nakamori, S.9
Hamamoto, Y.10
-
38
-
-
84912069731
-
A randomized phase II study of S-1 plus leucovorin versus S-1 alone in patients with Gemcitabine-refractory pancreatic cancer
-
abstract 406
-
Okusaka T, Ueno M, Omuro Y, Isayama H, Fukutomi A, Ikeda M, Mizuno M, Fukuzawa K, Hyodo I, Boku N. A randomized phase II study of S-1 plus leucovorin versus S-1 alone in patients with Gemcitabine-refractory pancreatic cancer. ESMO 2013; abstract 406
-
(2013)
ESMO
-
-
Okusaka, T.1
Ueno, M.2
Omuro, Y.3
Isayama, H.4
Fukutomi, A.5
Ikeda, M.6
Mizuno, M.7
Fukuzawa, K.8
Hyodo, I.9
Boku, N.10
-
39
-
-
0036569654
-
Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer
-
[PMID: 12007953]
-
Shinchi H, Takao S, Noma H, Matsuo Y, Mataki Y, Mori S, Aikou T. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002; 53: 146-150 [PMID: 12007953]
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.53
, pp. 146-150
-
-
Shinchi, H.1
Takao, S.2
Noma, H.3
Matsuo, Y.4
Mataki, Y.5
Mori, S.6
Aikou, T.7
-
40
-
-
2942648695
-
Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorouracil chemoradiation therapy
-
[PMID: 15169811]
-
Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004; 22: 2214-2232 [PMID: 15169811]
-
(2004)
J Clin Oncol
, vol.22
, pp. 2214-2232
-
-
Rich, T.A.1
Shepard, R.C.2
Mosley, S.T.3
-
41
-
-
0035501222
-
Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma
-
[PMID: 11597816]
-
Boz G, De Paoli A, Innocente R, Rossi C, Tosolini G, Pederzoli P, Talamini R, Trovò MG. Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2001; 51: 736-740 [PMID: 11597816]
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.51
, pp. 736-740
-
-
Boz, G.1
De Paoli, A.2
Innocente, R.3
Rossi, C.4
Tosolini, G.5
Pederzoli, P.6
Talamini, R.7
Trovò, M.G.8
-
42
-
-
0030938059
-
Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma
-
[PMID: 9118032]
-
Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997; 79: 1516-1520 [PMID: 9118032]
-
(1997)
Cancer
, vol.79
, pp. 1516-1520
-
-
Ishii, H.1
Okada, S.2
Tokuuye, K.3
Nose, H.4
Okusaka, T.5
Yoshimori, M.6
Nagahama, H.7
Sumi, M.8
Kagami, Y.9
Ikeda, H.10
-
43
-
-
78149320175
-
Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo
-
[PMID: 20878125]
-
Fukushima M, Sakamoto K, Sakata M, Nakagawa F, Saito H, Sakata Y. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 2010; 24: 1307-1313 [PMID: 20878125]
-
(2010)
Oncol Rep
, vol.24
, pp. 1307-1313
-
-
Fukushima, M.1
Sakamoto, K.2
Sakata, M.3
Nakagawa, F.4
Saito, H.5
Sakata, Y.6
-
44
-
-
33845652645
-
Phase i study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer
-
[PMID: 17189072]
-
Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Shirai Y, Nakagawa A, Kawakami H, Uno T, Ito H, Saisho H. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007; 67: 219-224 [PMID: 17189072]
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.67
, pp. 219-224
-
-
Sudo, K.1
Yamaguchi, T.2
Ishihara, T.3
Nakamura, K.4
Shirai, Y.5
Nakagawa, A.6
Kawakami, H.7
Uno, T.8
Ito, H.9
Saisho, H.10
-
45
-
-
34249790871
-
A phase i trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
-
[PMID: 17533388]
-
Ikeda M, Okusaka T, Ito Y, Ueno H, Morizane C, Furuse J, Ishii H, Kawashima M, Kagami Y, Ikeda H. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Br J Cancer 2007; 96: 1650-1655 [PMID: 17533388]
-
(2007)
Br J Cancer
, vol.96
, pp. 1650-1655
-
-
Ikeda, M.1
Okusaka, T.2
Ito, Y.3
Ueno, H.4
Morizane, C.5
Furuse, J.6
Ishii, H.7
Kawashima, M.8
Kagami, Y.9
Ikeda, H.10
-
46
-
-
34247617372
-
Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer
-
[PMID: 17437021]
-
Shinchi H, Maemura K, Noma H, Mataki Y, Aikou T, Takao S. Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer 2007; 96: 1353-1357 [PMID: 17437021]
-
(2007)
Br J Cancer
, vol.96
, pp. 1353-1357
-
-
Shinchi, H.1
Maemura, K.2
Noma, H.3
Mataki, Y.4
Aikou, T.5
Takao, S.6
-
47
-
-
79954425756
-
Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer
-
PMID: 20605363
-
Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, Tawada K, Imagumbai T, Araki H, Sakai M, Hatano K, Kawakami H, Uno T, Ito H, Yokosuka O. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011; 80: 119-125 [PMID: 20605363 DOI: 10.1016/j.ijrobp.2010.01.027]
-
(2011)
Int J Radiat Oncol Biol Phys
, vol.80
, pp. 119-125
-
-
Sudo, K.1
Yamaguchi, T.2
Ishihara, T.3
Nakamura, K.4
Hara, T.5
Denda, T.6
Tawada, K.7
Imagumbai, T.8
Araki, H.9
Sakai, M.10
Hatano, K.11
Kawakami, H.12
Uno, T.13
Ito, H.14
Yokosuka, O.15
-
48
-
-
84871391740
-
A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer
-
PMID: 22677367
-
Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, Miyakawa H, Ishii H, Furuse J, Sato K, Sato T, Okusaka T. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2013; 85: 163-169 [PMID: 22677367 DOI: 10.1016/j.ijrobp.2012.03.059]
-
(2013)
Int J Radiat Oncol Biol Phys
, vol.85
, pp. 163-169
-
-
Ikeda, M.1
Ioka, T.2
Ito, Y.3
Yonemoto, N.4
Nagase, M.5
Yamao, K.6
Miyakawa, H.7
Ishii, H.8
Furuse, J.9
Sato, K.10
Sato, T.11
Okusaka, T.12
-
49
-
-
84857039587
-
A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer
-
PMID: 21647560
-
Shinchi H, Maemura K, Mataki Y, Kurahara H, Sakoda M, Ueno S, Hiraki Y, Nakajo M, Natsugoe S, Takao S. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobiliary Pancreat Sci 2012; 19: 152-158 [PMID: 21647560 DOI: 10.1007/s00534-011-0400-y]
-
(2012)
J Hepatobiliary Pancreat Sci
, vol.19
, pp. 152-158
-
-
Shinchi, H.1
Maemura, K.2
Mataki, Y.3
Kurahara, H.4
Sakoda, M.5
Ueno, S.6
Hiraki, Y.7
Nakajo, M.8
Natsugoe, S.9
Takao, S.10
-
50
-
-
58249132914
-
Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer
-
PMID: 18828020
-
Kim HM, Bang S, Park JY, Seong J, Song SY, Chung JB, Park SW. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 535-541 [PMID: 18828020 DOI: 10.1007/s00280-008-0836-1]
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, pp. 535-541
-
-
Kim, H.M.1
Bang, S.2
Park, J.Y.3
Seong, J.4
Song, S.Y.5
Chung, J.B.6
Park, S.W.7
-
51
-
-
35748929435
-
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Up-regulation of thymidine phosphorylase
-
[PMID: 17762760]
-
Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J 2007; 13: 247-256 [PMID: 17762760]
-
(2007)
Cancer J
, vol.13
, pp. 247-256
-
-
Saif, M.W.1
Black, G.2
Roy, S.3
Bell, D.4
Russo, S.5
Eloubeidi, M.A.6
Steg, A.7
Johnson, M.R.8
Zelterman, D.9
Diasio, R.B.10
-
52
-
-
80051613675
-
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
-
PMID: 21709185
-
Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011; 29: 3037-3043 [PMID: 21709185 DOI: 10.1200/JCO.2010.33.8038]
-
(2011)
J Clin Oncol
, vol.29
, pp. 3037-3043
-
-
Crane, C.H.1
Varadhachary, G.R.2
Yordy, J.S.3
Staerkel, G.A.4
Javle, M.M.5
Safran, H.6
Haque, W.7
Hobbs, B.D.8
Krishnan, S.9
Fleming, J.B.10
Das, P.11
Lee, J.E.12
Abbruzzese, J.L.13
Wolff, R.A.14
-
53
-
-
0032127244
-
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
-
[PMID: 9849491]
-
Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281 [PMID: 9849491]
-
(1998)
Eur J Cancer
, vol.34
, pp. 1274-1281
-
-
Miwa, M.1
Ura, M.2
Nishida, M.3
Sawada, N.4
Ishikawa, T.5
Mori, K.6
Shimma, N.7
Umeda, I.8
Ishitsuka, H.9
-
54
-
-
84875783603
-
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial
-
PMID: 23474363
-
Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, Mc-Donald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013; 14: 317-326 [PMID: 23474363 DOI: 10.1016/S1470-2045(13)70021-4]
-
(2013)
Lancet Oncol
, vol.14
, pp. 317-326
-
-
Mukherjee, S.1
Hurt, C.N.2
Bridgewater, J.3
Falk, S.4
Cummins, S.5
Wasan, H.6
Crosby, T.7
Jephcott, C.8
Roy, R.9
Radhakrishna, G.10
Mc-Donald, A.11
Ray, R.12
Joseph, G.13
Staffurth, J.14
Abrams, R.A.15
Griffiths, G.16
Maughan, T.17
-
55
-
-
12144287320
-
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
-
[PMID: 15028824]
-
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210 [PMID: 15028824]
-
(2004)
N Engl J Med
, vol.350
, pp. 1200-1210
-
-
Neoptolemos, J.P.1
Stocken, D.D.2
Friess, H.3
Bassi, C.4
Dunn, J.A.5
Hickey, H.6
Beger, H.7
Fernandez-Cruz, L.8
Dervenis, C.9
Lacaine, F.10
Falconi, M.11
Pederzoli, P.12
Pap, A.13
Spooner, D.14
Kerr, D.J.15
Büchler, M.W.16
-
56
-
-
33846405332
-
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial
-
[PMID: 17227978]
-
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277 [PMID: 17227978]
-
(2007)
JAMA
, vol.297
, pp. 267-277
-
-
Oettle, H.1
Post, S.2
Neuhaus, P.3
Gellert, K.4
Langrehr, J.5
Ridwelski, K.6
Schramm, H.7
Fahlke, J.8
Zuelke, C.9
Burkart, C.10
Gutberlet, K.11
Kettner, E.12
Schmalenberg, H.13
Weigang-Koehler, K.14
Bechstein, W.O.15
Niedergethmann, M.16
Schmidt-Wolf, I.17
Roll, L.18
Doerken, B.19
Riess, H.20
more..
-
57
-
-
84885462618
-
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial
-
PMID: 24104372
-
Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310: 1473-1481 [PMID: 24104372 DOI: 10.1001/jama.2013.279201]
-
(2013)
JAMA
, vol.310
, pp. 1473-1481
-
-
Oettle, H.1
Neuhaus, P.2
Hochhaus, A.3
Hartmann, J.T.4
Gellert, K.5
Ridwelski, K.6
Niedergethmann, M.7
Zülke, C.8
Fahlke, J.9
Arning, M.B.10
Sinn, M.11
Hinke, A.12
Riess, H.13
-
58
-
-
70249099504
-
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
-
PMID: 19690548
-
Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101: 908-915 [PMID: 19690548 DOI: 10.1038/sj.bjc.6605256]
-
(2009)
Br J Cancer
, vol.101
, pp. 908-915
-
-
Ueno, H.1
Kosuge, T.2
Matsuyama, Y.3
Yamamoto, J.4
Nakao, A.5
Egawa, S.6
Doi, R.7
Monden, M.8
Hatori, T.9
Tanaka, M.10
Shimada, M.11
Kanemitsu, K.12
-
59
-
-
77956416112
-
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial
-
PMID: 20823433
-
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081 [PMID: 20823433 DOI: 10.1001/jama.2010.1275]
-
(2010)
JAMA
, vol.304
, pp. 1073-1081
-
-
Neoptolemos, J.P.1
Stocken, D.D.2
Bassi, C.3
Ghaneh, P.4
Cunningham, D.5
Goldstein, D.6
Padbury, R.7
Moore, M.J.8
Gallinger, S.9
Mariette, C.10
Wente, M.N.11
Izbicki, J.R.12
Friess, H.13
Lerch, M.M.14
Dervenis, C.15
Oláh, A.16
Butturini, G.17
Doi, R.18
Lind, P.A.19
Smith, D.20
Valle, J.W.21
Palmer, D.H.22
Buckels, J.A.23
Thompson, J.24
McKay, C.J.25
Rawcliffe, C.L.26
Büchler, M.W.27
more..
-
60
-
-
57849151618
-
The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: An in vivo study
-
[PMID: 19180995]
-
Eguchi T, Kodera Y, Nakanishi H, Yokoyama H, Ohashi N, Ito Y, Nakayama G, Koike M, Fujiwara M, Nakao A. The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: an in vivo study. In Vivo 2008; 22: 707-712 [PMID: 19180995]
-
(2008)
Vivo
, vol.22
, pp. 707-712
-
-
Eguchi, T.1
Kodera, Y.2
Nakanishi, H.3
Yokoyama, H.4
Ohashi, N.5
Ito, Y.6
Nakayama, G.7
Koike, M.8
Fujiwara, M.9
Nakao, A.10
-
61
-
-
31544483098
-
Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fluorescent proteintagged human gastric cancer cell line
-
[PMID: 16428473]
-
Yokoyama H, Nakanishi H, Kodera Y, Ikehara Y, Ohashi N, Ito Y, Koike M, Fujiwara M, Tatematsu M, Nakao A. Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fluorescent proteintagged human gastric cancer cell line. Clin Cancer Res 2006; 12: 361-368 [PMID: 16428473]
-
(2006)
Clin Cancer Res
, vol.12
, pp. 361-368
-
-
Yokoyama, H.1
Nakanishi, H.2
Kodera, Y.3
Ikehara, Y.4
Ohashi, N.5
Ito, Y.6
Koike, M.7
Fujiwara, M.8
Tatematsu, M.9
Nakao, A.10
-
62
-
-
35748946650
-
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
-
[PMID: 17978289]
-
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820 [PMID: 17978289]
-
(2007)
N Engl J Med
, vol.357
, pp. 1810-1820
-
-
Sakuramoto, S.1
Sasako, M.2
Yamaguchi, T.3
Kinoshita, T.4
Fujii, M.5
Nashimoto, A.6
Furukawa, H.7
Nakajima, T.8
Ohashi, Y.9
Imamura, H.10
Higashino, M.11
Yamamura, Y.12
Kurita, A.13
Arai, K.14
-
63
-
-
77951709577
-
Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages
-
PMID: 20422030
-
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267 [PMID: 20422030 DOI: 10.1371/journal.pmed.1000267]
-
(2010)
PLoS Med
, vol.7
-
-
Gillen, S.1
Schuster, T.2
Meyer Zum Büschenfelde, C.3
Friess, H.4
Kleeff, J.5
-
64
-
-
0035093234
-
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration
-
[PMID: 11258776]
-
Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8: 123-132 [PMID: 11258776]
-
(2001)
Ann Surg Oncol
, vol.8
, pp. 123-132
-
-
Breslin, T.M.1
Hess, K.R.2
Harbison, D.B.3
Jean, M.E.4
Cleary, K.R.5
Dackiw, A.P.6
Wolff, R.A.7
Abbruzzese, J.L.8
Janjan, N.A.9
Crane, C.H.10
Vauthey, J.N.11
Lee, J.E.12
Pisters, P.W.13
Evans, D.B.14
-
65
-
-
34250816847
-
A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin
-
[PMID: 17453298]
-
Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall SR. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007; 14: 2088-2096 [PMID: 17453298]
-
(2007)
Ann Surg Oncol
, vol.14
, pp. 2088-2096
-
-
Palmer, D.H.1
Stocken, D.D.2
Hewitt, H.3
Markham, C.E.4
Hassan, A.B.5
Johnson, P.J.6
Buckels, J.A.7
Bramhall, S.R.8
-
66
-
-
80255122607
-
A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer
-
PMID: 21913045
-
Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011; 15: 2059-2069 [PMID: 21913045 DOI: 10.1007/s11605-011-1659-7]
-
(2011)
J Gastrointest Surg
, vol.15
, pp. 2059-2069
-
-
Laurence, J.M.1
Tran, P.D.2
Morarji, K.3
Eslick, G.D.4
Lam, V.W.5
Sandroussi, C.6
-
67
-
-
84897019295
-
Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma
-
[PMID: 24393872]
-
Motoi F, Kawaguchi K, Aoki T, Kudo K, Yabuuchi S, Fukase K, Mizuma M, Sakata N, Otsutomo S, Morikawa T, Hayashi H, Nakagawa K, Okada T, Yoshida H, Naitoh T, Katayose Y, Egawa S, Unno M. [Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma]. Gan To Kagaku Ryoho 2013; 40: 1632-1636 [PMID: 24393872]
-
(2013)
Gan to Kagaku Ryoho
, vol.40
, pp. 1632-1636
-
-
Motoi, F.1
Kawaguchi, K.2
Aoki, T.3
Kudo, K.4
Yabuuchi, S.5
Fukase, K.6
Mizuma, M.7
Sakata, N.8
Otsutomo, S.9
Morikawa, T.10
Hayashi, H.11
Nakagawa, K.12
Okada, T.13
Yoshida, H.14
Naitoh, T.15
Katayose, Y.16
Egawa, S.17
Unno, M.18
-
68
-
-
0029996291
-
Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations
-
[PMID: 9173680]
-
Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996; 26: 395-403 [PMID: 9173680]
-
(1996)
Xenobiotica
, vol.26
, pp. 395-403
-
-
Shimada, T.1
Yamazaki, H.2
Guengerich, F.P.3
-
69
-
-
0033739717
-
Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro
-
[PMID: 11106261]
-
Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, Chiba K, Kawaguchi Y. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000; 6: 4409-4415 [PMID: 11106261]
-
(2000)
Clin Cancer Res
, vol.6
, pp. 4409-4415
-
-
Ikeda, K.1
Yoshisue, K.2
Matsushima, E.3
Nagayama, S.4
Kobayashi, K.5
Tyson, C.A.6
Chiba, K.7
Kawaguchi, Y.8
-
70
-
-
79952082092
-
Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
-
PMID: 21143703
-
Chuah B, Goh BC, Lee SC, Soong R, Lau F, Mulay M, Dinolfo M, Lim SE, Soo R, Furuie T, Saito K, Zergebel C, Rosen LS. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 2011; 102: 478-483 [PMID: 21143703 DOI: 10.1111/j.1349-7006.2010.01793.x]
-
(2011)
Cancer Sci
, vol.102
, pp. 478-483
-
-
Chuah, B.1
Goh, B.C.2
Lee, S.C.3
Soong, R.4
Lau, F.5
Mulay, M.6
Dinolfo, M.7
Lim, S.E.8
Soo, R.9
Furuie, T.10
Saito, K.11
Zergebel, C.12
Rosen, L.S.13
-
71
-
-
59849115856
-
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer
-
PMID: 18992248
-
Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-195 [PMID: 18992248 DOI: 10.1053/j.gastro.2008.09.067]
-
(2009)
Gastroenterology
, vol.136
, pp. 187-195
-
-
Farrell, J.J.1
Elsaleh, H.2
Garcia, M.3
Lai, R.4
Ammar, A.5
Regine, W.F.6
Abrams, R.7
Benson, A.B.8
Macdonald, J.9
Cass, C.E.10
Dicker, A.P.11
Mackey, J.R.12
-
72
-
-
84865474189
-
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma
-
PMID: 22705007
-
Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012; 143: 664-674. e1-6 [PMID: 22705007 DOI: 10.1053/j.gastro.2012.06.006]
-
(2012)
Gastroenterology
, vol.143
, pp. 664-674e16
-
-
Maréchal, R.1
Bachet, J.B.2
Mackey, J.R.3
Dalban, C.4
Demetter, P.5
Graham, K.6
Couvelard, A.7
Svrcek, M.8
Bardier-Dupas, A.9
Hammel, P.10
Sauvanet, A.11
Louvet, C.12
Paye, F.13
Rougier, P.14
Penna, C.15
André, T.16
Dumontet, C.17
Cass, C.E.18
Jordheim, L.P.19
Matera, E.L.20
Closset, J.21
Salmon, I.22
Devière, J.23
Emile, J.F.24
Van Laethem, J.L.25
more..
-
73
-
-
84872736743
-
Impact of the gene expressions of thymidylate synthase and dihydropyrimidine dehydrogenase on survival in patients enrolled in the ACTS-GC study
-
abstr 52
-
Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H. Impact of the gene expressions of thymidylate synthase and dihydropyrimidine dehydrogenase on survival in patients enrolled in the ACTS-GC study. J Clin Oncol 2012; 30 (suppl 4): abstr 52
-
(2012)
J Clin Oncol
, vol.30
-
-
Sasako, M.1
Terashima, M.2
Ichikawa, W.3
Ochiai, A.4
Kitada, K.5
Kurahashi, I.6
Sakuramoto, S.7
Katai, H.8
Sano, T.9
Imamura, H.10
|